DexCom (NASDAQ:DXCM) Given New $75.00 Price Target at Citigroup

DexCom (NASDAQ:DXCM) had its price target trimmed by Citigroup from $85.00 to $75.00 in a report released on Friday,Benzinga reports. The brokerage currently has a buy rating on the medical device company’s stock.

DXCM has been the subject of several other reports. Piper Sandler set a $75.00 price target on shares of DexCom and gave the company a “buy” rating in a research report on Friday. The Goldman Sachs Group decreased their price target on shares of DexCom from $104.00 to $89.00 and set a “buy” rating for the company in a research report on Wednesday, October 1st. TD Cowen decreased their price objective on shares of DexCom from $100.00 to $84.00 and set a “buy” rating for the company in a research report on Friday. Royal Bank Of Canada decreased their price objective on shares of DexCom from $100.00 to $85.00 and set an “outperform” rating for the company in a research report on Friday. Finally, William Blair raised shares of DexCom to a “strong-buy” rating in a research report on Thursday, July 31st. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $91.65.

DexCom Stock Down 14.6%

NASDAQ:DXCM opened at $58.22 on Friday. DexCom has a 1-year low of $56.44 and a 1-year high of $93.25. The company has a 50-day moving average of $70.94 and a 200 day moving average of $77.90. The firm has a market cap of $22.83 billion, a PE ratio of 40.43, a price-to-earnings-growth ratio of 1.43 and a beta of 1.47. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, October 30th. The medical device company reported $0.61 EPS for the quarter, beating the consensus estimate of $0.57 by $0.04. The business had revenue of $1.21 billion during the quarter, compared to analyst estimates of $1.18 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The company’s quarterly revenue was up 21.6% on a year-over-year basis. During the same period in the prior year, the firm posted $0.45 earnings per share. DexCom has set its FY 2025 guidance at EPS. As a group, research analysts anticipate that DexCom will post 2.03 EPS for the current fiscal year.

Insider Buying and Selling at DexCom

In related news, Director Mark G. Foletta sold 2,750 shares of the stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $81.06, for a total value of $222,915.00. Following the transaction, the director owned 51,121 shares in the company, valued at approximately $4,143,868.26. This represents a 5.10% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Kyle Malady sold 667 shares of the stock in a transaction that occurred on Friday, September 5th. The stock was sold at an average price of $80.86, for a total transaction of $53,933.62. Following the completion of the transaction, the director owned 22,667 shares in the company, valued at approximately $1,832,853.62. This trade represents a 2.86% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 5,383 shares of company stock worth $434,274 in the last 90 days. Corporate insiders own 0.32% of the company’s stock.

Institutional Investors Weigh In On DexCom

Hedge funds and other institutional investors have recently made changes to their positions in the company. Andra AP fonden acquired a new stake in shares of DexCom during the 2nd quarter worth approximately $26,000. Twin Peaks Wealth Advisors LLC purchased a new position in shares of DexCom during the 2nd quarter worth $26,000. SJS Investment Consulting Inc. raised its holdings in shares of DexCom by 4,800.0% during the 3rd quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock worth $26,000 after acquiring an additional 384 shares during the period. Golden State Wealth Management LLC raised its holdings in shares of DexCom by 211.2% during the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company’s stock worth $27,000 after acquiring an additional 264 shares during the period. Finally, Zions Bancorporation National Association UT purchased a new position in shares of DexCom during the 1st quarter worth $27,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.